| Parameter | JUQ‑103 Value | Unit | Comparison (JUQ‑102) | |-----------|--------------|------|----------------------| | Operating Frequency | [value] | GHz | [% change] | | Noise Figure | [value] | dB | [% change] | | Power Consumption | [value] | mW | [% change] | | Input/Output Count | [value] | – | [same/diff] | | Package Type | [value] | – | [same/diff] | | Temperature Range | [value] | °C | [same/diff] | | Production Yield (target) | [value] | % | – |
(Add or remove rows as needed.)
| Aspect | Summary |
|--------|---------|
| Acute toxicity | Limited human data; animal studies suggest LD₅₀ (oral, rat) ≈ 80 mg kg⁻¹. Overdose can provoke severe tachycardia, hypertension, seizures, and, rarely, cardiac arrest. |
| Chronic exposure | Chronic use of potent CB₁ agonists is associated with tolerance, dependence, and potential neurocognitive impairment. |
| Psychiatric risk | High‑potency cannabinoids can precipitate anxiety, panic attacks, psychosis, or exacerbate underlying mental illness. |
| Interactions | Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) may raise plasma levels; CYP inducers (e.g., rifampin) may lower them. |
| Handling precautions (lab) | - Use a certified chemical fume hood.
- Wear nitrile gloves, lab coat, and eye protection.
- Store in a locked, temperature‑controlled cabinet, away from light and moisture.
- Keep a material‑safety‑data‑sheet (MSDS) readily available. |
| First‑aid | If ingestion or inhalation occurs: monitor vitals, provide supportive care (oxygen, IV fluids), and consider benzodiazepines for agitation or seizures. Contact poison‑control centers promptly. | JUQ-103
| Risk | Probability (L/M/H) | Impact (L/M/H) | Mitigation Strategy | |------|----------------------|----------------|---------------------| | Supply‑chain disruption for specialty substrate | M | H | Qualify secondary vendor; stock safety inventory | | Yield below target in volume production | L | M | Implement inline SPC; adjust process windows | | Market adoption slower than forecast | M | H | Launch co‑development program with anchor customers | | Regulatory change (e.g., new quantum‑tech export rules) | L | M | Monitor policy updates; maintain legal counsel | | Parameter | JUQ‑103 Value | Unit |
Note: The exact naming conventions can differ slightly between chemical suppliers and forensic databases. Always verify the SMILES or InChI string when ordering or handling the material. | Risk | Probability (L/M/H) | Impact (L/M/H)
| Strengths | Weaknesses |
|-----------|------------|
| • Superior noise performance
• Compatibility with existing fabs | • Higher NRE cost
• Limited supply chain for specialty substrate |
| Opportunities | Threats |
| • Growing quantum‑computing market (CAGR ≈ 30 %)
• Potential government grants | • Rapid technology turnover
• Emerging alternative (e.g., photonic readout) |